嵌合抗原受体 (CAR) T 细胞疗法已成为癌症治疗中突破性的免疫治疗方法。为了克服当前离体 CAR T 细胞治疗产品的复杂性和高制造成本，近年来开发了直接在体内生产 CAR T 细胞的替代策略。这些策略涉及通过工程纳米载体或病毒载体直接输注 CAR 基因，以原位产生 CAR T 细胞。这篇综述全面概述了 T 细胞靶向原位 CAR 生成的最新进展。此外，它还确定了与体内 CAR T 方法相关的挑战以及克服这些问题的潜在策略。版权所有 © 2024 作者。由 Elsevier B.V. 出版。保留所有权利。

The Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a ground-breaking immunotherapeutic approach in cancer treatment. To overcome the complexity and high manufacturing cost associated with current ex vivo CAR T cell therapy products, alternative strategies to produce CAR T cells directly in the body have been developed in recent years. These strategies involve the direct infusion of CAR genes via engineered nanocarriers or viral vectors to generate CAR T cells in situ. This review offers a comprehensive overview of recent advancements in the development of T cell-targeted CAR generation in situ. Additionally, it identifies the challenges associated with in vivo CAR T method and potential strategies to overcome these issues.Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.